Visit the Zedira booth at ICDS!
Visit the Zedira booth at ICDS!
Start of phase 2a proof of concept study of ZED1227
Start of phase 2a proof of concept study of ZED1227
for the treatment of non-alcoholic fatty liver disease (NAFLD)
Zöliakie-Studienteilnehmer gesucht!
Zöliakie-Studienteilnehmer gesucht!
Für eine Wirksamkeitsstudie mit dem Studienmedikament ZED1227
(Link zu dzg-online.de)
Reversibly acting TG2 inhibitors
Reversibly acting TG2 inhibitors
Drug candidates for the treatment of fibrosis
Successful ISO9001:2015 recertification
Dr. Falk Pharma and Zedira announce successful completion of the phase 2a proof-of-concept study of ZED1227 for the treatment of Celiac Disease
Dr. Falk Pharma und Zedira verkünden den erfolgreichen Abschluss der Phase 2a-Studie mit ZED1227 zur Behandlung von Zöliakie
Reversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
Design of Oral FXIIIa Blockers as Safer Anticoagulants – Mission Impossible?
Microbial transglutaminase (MTG) enables efficient and site-specific conjugation to native antibodies without the need of antibody engineering